In the case of tumors, MHC I molecules present tumor-associated antigens (TAA) to CD8+ cytotoxic T-cells, and MHC II molecules present TAAs to CD4+ helper T-cells, thus facilitating an anti-tumor immune response [13]. The gene discussed is CD8A; the disease is neoplasm.